In Vivo Preclinical Testing Case Study:
How Melior Discovery Delivered Critical Data That Boosted Investor Confidence
Summary
Modifi Bio, a Yale spinout, needed orthotopic glioblastoma efficacy data but had no animal facility. Melior Discovery, with our demonstrated combined oncology and CNS expertise, built and validated intracranial glioblastoma models and delivered clean survival and imaging data, with a draft report in under a week. This preclinical efficacy data supported Modifi Bio’s investor confidence; Modifi Bio was later acquired by Merck for up to $1.3 billion.
Introduction
Modifi Bio, a Yale-spinout biotech developing a DNA-modifying small molecule for glioblastoma, needed reliable in vivo preclinical testing and efficacy data to validate its therapeutic approach and attract investment but had no in-house animal facility. Because brain cancer treatment requires incredibly complex in vivo models, Modifi Bio needed a preclinical in vivo CRO with a specific set of technical capabilities, without compromising efficiency or experience. Melior Discovery, a preclinical CRO with combined oncology and CNS expertise, built and validated orthotopic (intracranial) glioblastoma models and ran the preclinical efficacy studies, delivering clean survival and imaging data in days. The results powered Modifi Bio’s investor decks and funding discussions. Modifi Bio was later acquired by Merck in a deal worth up to $1.3 billion.
The Challenge: Generating In Vivo Preclinical Efficacy Data with In-House Resource Constraints
Modifi Bio, a biotech startup focused on innovative cancer treatment solutions, faced the daunting challenge of advancing its research with limited resources and a pressing need for specialized in vivo pharmacology studies. Without an in-house animal facility for performing critical in vivo pharmacology work, Modifi Bio had previously relied on academic collaborations to test its novel drug discovery approaches in tumor models.
However, the fluidity of academic timelines led to project unpredictability and introduced costly delays. Because their focus on brain cancer treatment (specifically glioblastoma studies) requires incredibly complex in vivo models, Modifi Bio needed an in vivo CRO with a specific set of technical capabilities, without compromising efficiency or experience. They required a reliable partner that could execute a project on time and to a high standard.
Melior's Solution: Efficient Technical Execution & Combined Oncology and CNS Expertise
From day one, Melior applied its deep oncology knowledge alongside its neuroscience and Central Nervous System (CNS) background, a combination essential for the intricate brain surgeries Modifi Bio’s glioblastoma studies demanded.
Model Establishment
Using Modifi Bio’s engineered cell lines, Melior established in vivo models with both subcutaneous implants and intracranial (orthotopic) tumor implantation. Orthotopic implantation into the brain was essential for accurately assessing efficacy in a biologically relevant context.
Model Validation
Melior validated the model by evaluating growth kinetics and take rates, successfully replicating and reproducing Modifi Bio’s earlier in-house and academic data.
Study Expansion
On that validated foundation, Melior completed two significant studies testing Modifi Bio’s drugs alongside reference compounds, generating clean, comprehensive outcomes and critical data.
The Outcome: Proof That Powered Investor Confidence
The technical proficiency of Melior’s in vivo preclinical efficacy testing led to rapid success and delivered significant outcome-driven results:
- High-Quality, Reliable Data: Melior produced premium, clean data featuring survival studies and bioluminescent imaging that effectively demonstrated the treatment’s impact on brain tumor models.
- Rapid Timeline Turnaround: The draft report was delivered in less than a week, and the final report was finalized in a matter of days after study completion. This rapid delivery allowed Modifi Bio to overcome operational and financial constraints promptly.
- Adaptability & Effective Communication: Melior provided a highly flexible approach, demonstrating responsiveness and a willingness to accommodate on-the-fly changes in study protocols based on new insights. Regular updates ensured Modifi Bio was continually informed about the progress of the work, functioning essentially as an extension of their internal team.
- Investor Confidence & Strategic Value: The data produced was instrumental for ongoing funding discussions and strategic objectives. Modifi Bio utilized Melior’s compelling data visualizations, such as beautiful survival curves comparing their agent versus the control, to create powerful investor decks that enhanced investor confidence and catalyzed funding discussions.
Frequently Asked Questions
Melior Discovery, a preclinical in vivo CRO with combined oncology and CNS expertise, builds and validates orthotopic (intracranial) glioblastoma models and runs the associated preclinical efficacy studies. This combination of neuroscience and oncology capability is what makes orthotopic brain tumor work possible, as demonstrated in the Modifi Bio program.
Preclinical efficacy testing is the in vivo evaluation of a drug candidate in animal models of a disease to determine whether it produces a meaningful therapeutic effect before human trials. For programs like Modifi Bio’s, this in vivo preclinical testing provides the first in vivo proof-of-concept — a critical value-inflection point for investors and partners.
An orthotopic glioblastoma model places tumor cells in their biologically relevant location — the brain, via intracranial implantation, rather than under the skin. This yields a far more accurate picture of how a therapy will perform against brain cancer, but requires the specialized surgical and CNS expertise of a preclinical in vivo CRO.
Academic collaborations introduced unpredictable timelines and costly delays. A specialized preclinical CRO like Melior offered reliable, on-time execution to a high standard, combined with the specific oncology and CNS capabilities glioblastoma models demand.
Clear, high-quality efficacy data, such as survival curves and tumor imaging comparing a drug candidate to control, give investors concrete evidence that a therapy works. Modifi Bio featured Melior’s in vivo preclinical efficacy testing data visualizations in its investor decks to build confidence and advance funding discussions.
Interested in conducting a preclinical efficacy study with your therapeutic candidate?
If you are interested in learning more about Melior’s preclinical efficacy study services, please contact us to start the conversation today!